#London #United Kingdom #biotechnology #Fund V #Medicxi

Medicxi Announces €500 Million Fund V

London, November 14, 2025 – Medicxi, a prominent venture capital firm focused on life sciences in Europe, has announced the successful closing of its latest fund, Medicxi V, which amounts to an impressive €500 million. This new fund aims to empower innovative biotechnology companies that possess clear product visions aimed at transforming patient care.

The latest fund has been oversubscribed, garnering strong support from both existing limited partners and a select group of new institutional investors. Medicxi V will adhere to the firm’s proven asset-centric investment model, which has enabled it to create 16 new companies and provide over $1 billion in value through clinical data successes in previous investments, including stakes in Vaxcyte, Merus, and Abivax.

Medicxi has a robust track record since its last fundraise, marked by significant accomplishments. They have realized over 20 positive clinical data readouts and executed strategic acquisitions, reflecting the firm’s ability to generate substantial returns while focusing on drug development. The strategic investments are set to continue, as the Fund allocates capital to support both the creation of new asset-focused biotech companies and investments in existing companies that align with Medicxi's investment strategy.

"Medicxi's longstanding success is rooted in its unique partnerships with top global pharmaceutical companies and a team recognized for their expertise in drug discovery and development," said Francesco De Rubertis, Co-founder and Partner at Medicxi. "With the new €500 million fund, we are positioned to deliver critical capital, expertise, and experience that can unlock transformative therapies for patients."

Giovanni Mariggi, another Co-founder and Partner at Medicxi, highlighted the firm’s rapidly scaling capital-efficient investment strategy. "In the last decade alone, we have successfully raised six funds, culminating in a total of over €2 billion. Thanks to the unwavering support from our existing and new limited partners, we look forward to continuing our investments in groundbreaking science that accelerates the discovery of life-changing medicines for patients."

In addition to the new fund announcement, Medicxi has promoted Shyam Masrani to Partner. Masrani has been instrumental in Medicxi's investments, leading significant contributions to companies such as Merus and ProfoundBio, while also serving on the boards of other emerging biotechnology firms.

The investment partners in Fund V include recognized names in the industry: Francesco De Rubertis, Giovanni Mariggi, Nick Williams, and Shyam Masrani. Their collective experience and commitment to advancing medical innovation position Medicxi as a formidable player in the venture capital domain.

About Medicxi

Medicxi provides a focused investment strategy within the healthcare sector, dedicated to creating and supporting companies spanning the entire drug development lifecycle. Their investment philosophy is underscored by deep expertise and industry connections, allowing them to identify and address clear unmet medical needs through early and late-stage therapeutics.

For more information, visit www.medicxi.com.